Redox-sensitive cross-linking enhances albumin nanoparticle function as delivery system for photodynamic cancer therapy.

Photodynamic cancer therapy is still limited in its efficiency because of a lack of targeted methods avoiding non-specific toxicity. To overcome this we developed a system that is solely effective upon cellular uptake and intracellular activation by incorporating redox-sensitive chemistry. We used a nanoprecipitation method to obtain human serum albumin nanoparticles (HSA NP) with a diameter of 295 ± 5 nm and decorated them with the photosensitizer (PS) chlorin e6 (Ce6). The NP were stabilized using a redox-sensitive cross-linker to create a smart drug delivery system that is activated only upon NP disintegration in the reducing intracellular environment. Indeed, our drug delivery NP broke down in an environment emulating the reducing intracellular environment with 10 mM glutathione, but not under extracellular conditions. In contrast, the control cross-linked with glutaraldehyde did not break down in the reducing environment. Upon NP disintegration Ce6 fluorescence doubled as the result of diminished self-quenching. While the Ce6-HSA NP did not produce a significant amount of singlet oxygen upon irradiation, NP disintegration restored singlet oxygen production to about half of the value generated by the free Ce6. In vitro experiments with HeLa cells showed that the smart system was able to kill up to 81% of the cells while the glutaraldehyde cross-linked control only killed 56% of them at a drug concentration of 10 ng/ml. Also, Ce6 immobilization in HSA NP prevented dark toxicity in three different cell lines. For the first time, we demonstrate that it is possible to design a smart NP drug delivery system delivering a PS drug to cancer cells while avoiding toxicity prior to the uptake and irradiation. This finding may provide a means of designing more efficient PDT in cancer treatment.

[1]  J. Pellois,et al.  Photodamage of lipid bilayers by irradiation of a fluorescently labeled cell-penetrating peptide. , 2014, Biochimica et biophysica acta.

[2]  A. Dube,et al.  Photodynamic efficacy of chlorin p6: a pH dependent study in aqueous and lipid environment. , 2008, Journal of photochemistry and photobiology. B, Biology.

[3]  Ick Chan Kwon,et al.  Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[4]  A. Habeeb,et al.  Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. , 1966, Analytical biochemistry.

[5]  A J Sinskey,et al.  Oxidized redox state of glutathione in the endoplasmic reticulum. , 1992, Science.

[6]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[7]  Xingping Zhou,et al.  Magnetic chitosan nanoparticles as a drug delivery system for targeting photodynamic therapy , 2009, Nanotechnology.

[8]  Anna M. Molina,et al.  Activation of caspase-dependent apoptosis by intracellular delivery of cytochrome c-based nanoparticles , 2014, Journal of Nanobiotechnology.

[9]  H von Briesen,et al.  Optimization of the preparation process for human serum albumin (HSA) nanoparticles. , 2003, International journal of pharmaceutics.

[10]  Sarah A Heerboth,et al.  Drug Resistance in Cancer: An Overview , 2014, Cancers.

[11]  J. Brash,et al.  X-ray microscopy studies of protein adsorption on a phase segregated polystyrene/polymethylmethacrylate surface. 2. Effect of pH on site preference. , 2008, The journal of physical chemistry. B.

[12]  V. Vogel,et al.  Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. , 2008, International journal of pharmaceutics.

[13]  H. Maeda Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  D. Perrier,et al.  Analysis of albumin microsphere preparation , 1984 .

[15]  R. Allison Photodynamic therapy: oncologic horizons. , 2014, Future oncology.

[16]  Matthias Wacker,et al.  Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties. , 2010, International journal of pharmaceutics.

[17]  Matthias G. Wacker,et al.  Photosensitizer loaded HSA nanoparticles II: in vitro investigations. , 2011, International journal of pharmaceutics.

[18]  Photodynamic responsiveness of human leukemia Jurkat/A4 cells with multidrug resistant phenotype. , 2014, Experimental oncology.

[19]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Anthony W. Parker,et al.  Time-resolved fluorescence imaging of photosensitiser distributions in mammalian cells using a picosecond laser line-scanning microscope , 2001 .

[22]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[23]  M. Kuroki,et al.  Tumor-targeted photodynamic therapy. , 2013, Anticancer research.

[24]  M. DeRosa Photosensitized singlet oxygen and its applications , 2002 .

[25]  A. Coombes,et al.  Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. , 1993, Journal of drug targeting.

[26]  Zheng Huang,et al.  Photodynamic Therapy for Treatment of Solid Tumors — Potential and Technical Challenges , 2008, Technology in cancer research & treatment.

[27]  Khaled Greish,et al.  Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. , 2010, Methods in molecular biology.

[28]  Hans Leuenberger,et al.  Albumin Nanospheres as Carriers for Passive Drug Targeting: An Optimized Manufacturing Technique , 2004, Pharmaceutical Research.

[29]  I. Kraljić,et al.  A NEW METHOD FOR THE DETECTION OF SINGLET OXYGEN IN AQUEOUS SOLUTIONS , 1978 .

[30]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[31]  R. Boyle,et al.  Photodynamic therapy: novel third‐generation photosensitizers one step closer? , 2008, British journal of pharmacology.

[32]  Indrajit Roy,et al.  In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. , 2010, ACS nano.

[33]  C H Sibata,et al.  Bio-nanotechnology and photodynamic therapy--state of the art review. , 2008, Photodiagnosis and photodynamic therapy.

[34]  D. Nowis,et al.  Light and Light Sources for Pdt Direct Tumor Damage Mechanisms of Photodynamic Therapy , 2005 .

[35]  S. Hackbarth,et al.  Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations. , 2009, Journal of photochemistry and photobiology. B, Biology.

[36]  R. Gurny,et al.  Quenching-induced deactivation of photosensitizer by nanoencapsulation to improve phototherapy of cancer , 2009, Journal of drug targeting.

[37]  J. Kulbacka,et al.  Polymeric micelles for enhanced Photofrin II ® delivery, cytotoxicity and pro-apoptotic activity in human breast and ovarian cancer cells. , 2014, Photodiagnosis and photodynamic therapy.

[38]  J. Spikes Chlorins as photosensitizers in biology and medicine. , 1990 .